Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2745
- Registration Number
- NCT00700960
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Paris La Défense, France
An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3024
- Registration Number
- NCT00700648
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1531
- Registration Number
- NCT00700765
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: soluble human insulin
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4099
- Registration Number
- NCT00698126
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Rome, Italy
Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2308
- Registration Number
- NCT00699179
- Locations
Novo Nordisk Investigational Site, Belgrade, Former Serbia and Montenegro
Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: biphasic human insulin
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 397
- Registration Number
- NCT00698802
An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5926
- Registration Number
- NCT00698269
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
Completed
- Conditions
- Congenital Bleeding DisorderCongenital FVII DeficiencyGlanzmann's DiseaseAcquired Bleeding DisorderAcquired Haemophilia
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT00697320
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 509
- Registration Number
- NCT00696995
- Locations
- 🇫🇮
Novo Nordisk Investigational Site, Lahti, Finland
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 415
- Registration Number
- NCT00696657
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Trowbridge, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath